The diagnosis and treatment of lentigo maligna (LM) present challenges to the dermatopathologist and clinician, who struggle to make an accurate diagnosis, devise a treatment plan appropriate to the age and health status of the patient, and determine when surgical margins are truly negative. All these issues create complexity when managing an increasingly common tumor.1 Because most LM lesions occur in cosmetically sensitive areas —usually on the head and neck2 —surgical morbidity is an unavoidable consequence of staged excisions with relatively large defects. When confronted with an ambiguous pathology report, such as “atypical junctional melanocytic hyperplasia with severe atypia on sun-damaged skin ” or “evolving melanoma in situ, ” the clinician is caught on the horns of a dilemma: is this LM or not? If so, what treatment approach strikes the appropriate balance between the relatively low risk of the tumor becoming invasive (if the LM began when the patient was 65 years old, the estimated lifetime risk is 3.3%)3 vs the morbidity of a large staged excision? When it comes to treatment, if ever there was a tumor for which one size does not fit all, it is LM.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.